Actavis CEO Says Health Law May Boost Generics Use

Feb. 15 (Bloomberg) -- Paul Bisaro, chief executive officer of Actavis Inc., talks about the impact of the U.S. Affordable Care Act on the pharmaceutical industry, so-called biosimilars, generic versions of biotechnology drugs, and the outlook for growth. He speaks with Mark Crumpton on Bloomberg Television's "Bottom Line." (Source: Bloomberg)

Most Recent Videos

How Apple Conquered China Market: Bloomberg West (01/30)
16:59 - Jan. 30 -- Full episode of "Bloomberg West." Guests: GGV Capital's Hans Tung, Strategic Analytics' Neil Mawston, Evercore ISI's Ken Sena, CKE Restaurants CEO Andrew Puzder, Boost VC CEO Adam Draper and Zebra Technologies' Jill Stelfox.
  • Should Amazon Spin Off Its Growing Cloud Business?
  • TripAdvisor's Top Pick: Chicago's Langham Hotel
  • Dan Marino: Roger Goodell Has Done a Really Good Job